Fact CheckerSign in

NCT07606638Enrolling by invitation

Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients

Source: ClinicalTrials.gov · Last updated 26 May 2026

Brief summary (registry, in English)

This randomized clinical study was designed to compare two pain treatment approaches for adults with oral cancer who had moderate to severe pain. Oral cancer pain may occur because of tumor growth, local tissue damage, inflammation, ulceration, or nerve involvement. Standard pain treatment often includes opioid medicines, but these medicines may cause side effects such as sedation, nausea, constipation, dizziness, tolerance, or dependence. In some patients, pain may also have a nerve-related or inflammatory component, where medicines such as pregabalin and naproxen sodium may provide additional benefit. A total of 98 eligible adult patients with histopathology-confirmed oral cancer and a baseline Visual Analog Scale pain score of 4 or more were included. Patients were randomly assigned into two treatment groups. One group received oral tramadol 50 mg every 4 hours, with dose adjustment according to pain relief and tolerability. The other group received oral pregabalin 75 mg twice daily with naproxen sodium 550 mg twice daily. Both treatments were given for 7 days under clinical monitoring. Pain intensity was measured using the Visual Analog Scale at baseline, day 3, and day 7. The main outcome was the mean reduction in pain score from baseline to day 7. Effective pain relief was defined as at least 50% reduction in the baseline pain score after 7 days of treatment. Side effects such as sedation, nausea or vomiting, constipation, dizziness, and gastrointestinal discomfort were also recorded. Patient satisfaction with pain control was assessed at the end of treatment.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
98 (estimated)
First submitted
19 May 2026
Start date
1 Feb 2026
Primary completion date
30 Jul 2026
Lead sponsor
Mayo Hospital Lahore
NCT number
NCT07606638

What you commit to

  • Study type: Interventional
  • Planned participants: 98
  • From 1 Feb 2026 to the primary completion date, 30 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concurrent use of other strong analgesics

Other illness

  • Known allergy to morphine, pregabalin, or NSAIDs
  • History of renal impairment, gastrointestinal bleeding, or peptic ulcer disease
  • Psychiatric illness or cognitive impairment interfering with pain assessment

Other

  • Pregnancy or lactation

Who the study is looking for

  • Patients aged 18 years or older
  • Histopathology confirmed diagnosis of oral cancer
  • Experiencing moderate to severe pain (VAS ≥ 4)
  • Either opioid-naïve or off opioids for at least one week
  • Able to provide informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Hospital Lahore
Coordinator of this site? Confirm its status
LahorePakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.